Vertex Pharmaceuticals Inc. closed $111.56 below its 52-week high ($519.88), which the company achieved on November 8th.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

this drop in the stock is still an unambiguously appealing opportunity to buy the dip. Overall, Vertex's data on the candidate's efficacy for general acute pain look better than the new data on ...

This comprehensive analysis examines Vertex's position in the market ... Vertex has demonstrated robust financial performance, with its stock price increasing by 109% year-to-date as of December ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Artivion, Inc. AORT: This medical device and tissue ...

This was the stock's third consecutive day of gains.

Vertex stock plummeted Thursday after the company's non-opioid pain ... up to make a statistical comparison between ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $408.18 which represents a slight increase of $2.91 or 0.72% from the prior close of $405.27. The stock opened at $401.53 ...

The analysis suggest that trial design innovation may better ... and bunionectomies (NCT05553366). "Vertex’s stock hurt after ...

Vertex also conducted post-hoc analyses showing ... Benzinga Pro - Click here to start Your 14-Day Trial Now! Get the latest stock analysis from Benzinga?

Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. Market Capitalization Analysis ... essential indicators of stock performance, provided ...

Vertex Minerals Ltd. (AU:VTX) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street ...